NRG Therapeutics, Maven, BC Platforms
BC Platforms Raises USD20M in Growth Financing
BC Platforms, a Zurich, Switzerland-based provider of healthcare data management and analytics solutions, raised $20M in Growth financing.
The round was led by Jolt Capital.
The company intends to use the funds to accelerate the expansion of the its data footprint, R&D coverage and growth of its sales and marketing operations.
Led by CEO Tero Silvola, BCP provides genomic data discovery and analytics platforms which convert complex biological information collected in the healthcare setting into actionable insights. Data generated, harmonised, and managed from diverse biobanks and healthcare institutions is made accessible to pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, BCP enables stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Its genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information.
BC Platforms Raises USD20M in Growth Financing - FinSMEs
BC Platforms, a Zurich, Switzerland-based provider of healthcare data management and analytics solutions, raised $20M in Growth financing
NRG Therapeutics Raises £16M in Series A Funding
NRG Therapeutics, a Stevenage, UK-based neuroscience company, raised £16M in Series A funding.
The round was led by Omega Funds with participation from Brandon Capital and Parkinson’s Virtual Biotech. In connection with the financing, Omega Funds Managing Director Claudio Nessi and Partner Francesco Draetta, as well as Brandon Capital Partner Jonathan Tobin, have joined its Board of Directors.
The company intends to use the funds to advance its first-in-class brain-penetrant small molecules through IND-enabling studies.
Led by CEO Dr Neil Miller, NRG Therapeutics is applying science in the field of mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS (also known as motor neurone disease or MND). Its pre-clinical pipeline includes small molecule assets which inhibit the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action.
NRG Therapeutics Raises £16M in Series A Funding
NRG Therapeutics, a Stevenage, UK-based neuroscience company, raised £16M in Series A funding.
Zenas BioPharma Raises $118M in Series B Funding
Zenas BioPharma, a Waltham, MA-based biopharmaceutical company, raised $118M in Series B funding.
The round was led by Enavate Sciences, with participation from Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners, Superstring Capital, Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund, and Xencor. In connection with the Series B financing, Enavate Sciences CEO Jim Boylan, Longitude Capital Co-founder and Managing Director Patrick Enright, and Vivo Capital Managing Partner Hongbo Lu have joined the Zenas Board of Directors.
The company intends to use the funds for the clinical advancement of its lead product candidate Obexelimab, including a global Phase 3 registration trial in patients with IgG4-related disease (IgG4-RD), which will be initiated in late 2022. In addition, the new funding will progress other global autoimmune disease programs into clinical development in 2023.
Led by Lonnie Moulder, Zenas BioPharma is a biopharmaceutical company committed to advancing and commercializing immune-based therapies for patients around the world. The company is advancing Obexelimab, an investigational phase III-stage, novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. In early-stage clinical studies, obexelimab effectively demonstrated inhibition of B-cell function without depleting the cells and generated an encouraging treatment effect in patients with multiple autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.
IgG4-RD is a chronic and serious, fibroinflammatory disease typically affecting multiple organs and sites (e.g., pancreas, liver, kidney, bile duct, salivary and lacrimal glands).
Zenas BioPharma Raises $118M in Series B Funding
Zenas BioPharma, a Waltham, MA-based biopharmaceutical company, raised $118M in Series B funding
Maven Clinic Raises $90M in Series E Funding
Maven Clinic, a New York-based provider of a virtual clinic in women’s and family health, raised $90m in Series E funding.
The round was led by General Catalyst, with participation from CVS Health Ventures, La Famiglia, Intermountain Ventures, Sequoia, Oak HC/FT, Icon Ventures, Dragoneer Investment Group, and Lux Capital. This brings Maven’s total funding to $300m.
The company intends to use the funds to continue to invest in personalization across its platform to drive meaningful outcomes in both commercial and Medicaid populations, enhance localization of resources to meet the cultural and country-specific needs of its global members, and increase depth of support across all family and reproductive health life stages.
Founded in 2014 by CEO Kate Ryder, Maven is a virtual clinic for women’s and family health, offering continuous, holistic care for fertility and family building through maternity, parenting, pediatrics and menopause. Its digital programs are used by employers and health plans to reduce costs and drive better maternal health outcomes, as well as enhance DE&I in benefits programs.
The technology platform offers 24/7 virtual care, easy financial reimbursement, peer communities, and concierge support to members across 175 countries.
Maven Clinic Raises $90M in Series E Funding
Maven Clinic, a New York-based provider of a virtual clinic in women’s and family health, raised $90M in Series E funding
Zelis Acquires Payspan
Zelis, a Bedminster, NJ-based healthcare company, acquired Payspan, a Jacksonville, FL-based provider of a healthcare electronic payment and reimbursement automation services.
The amount of the deal was not disclosed.
With the acquisition, Zelis will offer more options to both payers and their clients through a new payments and communications platform.
Led by CEO Rob Pinataro, Payspan is a provider of healthcare electronic payment and reimbursement automation services, leveraging healthcare payment network to drive value-based care reimbursement, improve the patient experience and reduce costs for health plans and providers.
Led by CEO Amanda Eisel, Zelis provides a connected platform that aligns interests across healthcare insurers, providers, and consumers. Its platform is serving more than 700 payers, including the top-5 national health plans, BCBS insurers, regional health plans, TPAs and self-insured employers, and millions of healthcare providers and consumers, across the financial experience to identify, optimize, and solve problems with technology built by healthcare experts — driving real, measurable results for clients.
